Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 19, 2019 - Issue 5
Submit an article Journal homepage
112
Views
6
CrossRef citations to date
0
Altmetric
Special Report

Netupitant plus palonosetron is a cost-effective treatment for the prophylaxis of chemotherapy-induced nausea and vomiting in highly and moderately emetogenic cancer treatment

Jacopo GiulianiDepartment of Oncology, Mater Salutis Hospital, Legnago, VR, ItalyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-4096-2514View further author information
ORCID Icon &
Andrea BonettiDepartment of Oncology, Mater Salutis Hospital, Legnago, VR, ItalyView further author information
Pages 505-508 | Received 17 May 2019, Accepted 29 Jul 2019, Published online: 04 Aug 2019

Citations (6)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Shiraz Halloush, Abdullah A. Alhifany, Nimer S. Alkhatib, Abdel Qader Al Bawab, Batool AL-Qawasmeh, Esra’a Al Shawakri & Jim Koeller. (2022) Cost-effectiveness of palonosetron and dexamethasone-based triple and quadruple regimens in preventing highly emetogenic chemotherapy-induced nausea and vomiting. Current Medical Research and Opinion 38:4, pages 571-577.
Read now

Articles from other publishers (5)

Rudolph M. Navari, Winnie W. Nelson, Sofia Shoaib, Risho Singh, Weiping Zhang & William L. Bailey. (2023) Real-World Treatment Outcomes, Healthcare Resource Use, and Costs Associated with Antiemetics Among Cancer Patients on Cisplatin-Based Chemotherapy. Advances in Therapy 40:7, pages 3217-3226.
Crossref
Winnie W Nelson, Varun Vaidya, Jeffery A Scott, Brandon Wang, Hunter Lambert, Benjamin Holmes & William L Bailey. (2023) Antiemetic use and chemotherapy induced nausea and vomiting related hospitalization costs after highly or moderately emetogenic chemotherapy. Future Oncology 19:1, pages 29-36.
Crossref
Miho Takemura, Kenji Ikemura, Masayoshi Kondo, Fumihiro Yamane, Mikiko Ueda & Masahiro Okuda. (2022) Concomitant palonosetron ameliorates cisplatin-induced nephrotoxicity, nausea, and vomiting: a retrospective cohort study and pharmacovigilance analysis. Journal of Pharmaceutical Health Care and Sciences 8:1.
Crossref
Jonas Nilsson, Vittoria Piovesana, Marco Turini, Claudio Lezzi, Jennifer Eriksson & Matti Aapro. (2022) Cost-effectiveness analysis of NEPA, a fixed-dose combination of netupitant and palonosetron, for the prevention of highly emetogenic chemotherapy-induced nausea and vomiting: an international perspective. Supportive Care in Cancer 30:11, pages 9307-9315.
Crossref
Jacopo Giuliani & Andrea Bonetti. (2020) Cost-effectiveness of newer regimens for the prophylaxis of chemotherapy-induced nausea and vomiting: review of the literature and real-world data. Current Opinion in Oncology 32:4, pages 269-273.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.